^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CXCR2 and NGFR transduced TIL
i
Other names: CXCR2 and NGFR transduced TIL, T-Cells transduced with CXCR2, CXCR2-transduced autologous tumor infiltrating lymphocytes, T-Cells transduced with CXCR2 and NGFR, T-cells transduced with chemokine (C-X-C motif) receptor 2 and nerve growth factor receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
UT MD Anderson Cancer Center
Drug class:
CXCR2 antagonist, Nerve growth factor antagonist
Related drugs:
over1year
NCI-2014-02655: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (clinicaltrials.gov)
P1/2, N=10, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2024 --> Apr 2023 | Trial primary completion date: Jan 2024 --> Apr 2023
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • NGFR (Nerve Growth Factor Receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • CXCR2 and NGFR transduced TIL
3years
NCI-2014-02655: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (clinicaltrials.gov)
P1/2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2021 --> Jan 2024 | Trial primary completion date: Jan 2021 --> Jan 2024
Clinical • Trial completion date • Trial primary completion date
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • NGFR (Nerve Growth Factor Receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • CXCR2 and NGFR transduced TIL
almost5years
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (clinicaltrials.gov)
P1/2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=15 --> 10 | Trial primary completion date: Jan 2020 --> Jan 2021
Clinical • Enrollment closed • Enrollment change • Trial primary completion date
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • NGFR (Nerve Growth Factor Receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
fludarabine IV • Proleukin (aldesleukin) • CXCR2 and NGFR transduced TIL • cyclophosphamide intravenous
Share via
